Austar Lifesciences Limited Updated Consolidated Group Earnings Guidance for the six months ending 30 June 2023. For the period, the Group is expected to record a loss attributable to the owners of the Company of approximately RMB 40 million for the six months ended 30 June 2023, as compared with a profit attributable to the owners of the Company of approximately RMB 45.8 million for the six months ended 30 June 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.71 HKD | -2.74% | -6.58% | -54.49% |
Mar. 26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-54.49% | 47.9M | |
-3.79% | 184B | |
-0.84% | 108B | |
-3.75% | 67.82B | |
+3.45% | 51.05B | |
+9.04% | 44.67B | |
+3.40% | 41.78B | |
+3.21% | 26.78B | |
+3.66% | 26.59B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Updates Consolidated Group Earnings Guidance for the Six Months Ending June 30, 2023